Dapagliflozin improves outcomes in HFmrEF and HFpEF

被引:0
|
作者
Fernandez-Ruiz, Irene
机构
[1] Nature Reviews Cardiology,
关键词
D O I
10.1038/s41569-022-00782-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In patients with heart failure (HF) with mildly reduced or preserved ejection fraction, the SGLT2 inhibitor dapagliflozin reduces the risk of worsening HF or cardiovascular death by 18%, reduces total HF events and cardiovascular deaths by 23% and improves HF symptoms, according to findings from the DELIVER trial.
引用
收藏
页码:719 / 719
页数:1
相关论文
共 50 条
  • [31] Sex differences in biomarkers over time - covering the HFrEF, HFmrEF and HFpEF spectrum
    Van Wijk, S. Sandra
    Aizpurua, A. M. A. Barandiaran
    Maeder, M.
    Van Empel, V.
    Brunner-La Rocca, H. P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 63 - 63
  • [32] What are the differences between HFrEF, HFmrEF and HFpEF patients admitted for acute heart failure?
    Goncalvesova, E.
    Lesny, P.
    Luknar, M.
    Dankova, M.
    Simovicova, V.
    Kovacova, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 45 - 46
  • [33] Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria
    Patrick, Stephanie A.
    Dabal, Tracey D.
    Jackson, Christopher D.
    Halalau, Alexandra
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (09) : 2915 - 2917
  • [34] Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria
    Stephanie A. Patrick
    Tracey D. Dabal
    Christopher D. Jackson
    Journal of General Internal Medicine, 2021, 36 : 2915 - 2917
  • [35] Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study
    Ozlek, Bulent
    Ozlek, Eda
    Agus, Hicaz Zencirkiran
    Tekinalp, Mehmet
    Kahraman, Serkan
    Cil, Cem
    Celik, Oguzhan
    Basaran, Ozcan
    Dogan, Volkan
    Kaya, Bedri Caner
    Rencuzogullari, Ibrahim
    Osken, Altug
    Bekar, Lutfu
    Cakir, Mustafa Ozan
    Celik, Yunus
    Mert, Kadir Ugur
    Sancar, Kadriye Memic
    Sevinc, Samet
    Mert, Gurbet Ozge
    Biteker, Murat
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 61 : 88 - 95
  • [36] Left atrial function in HFpEF and HFmrEF patients; relation to pulmonary artery systolic pressure
    Vrettos, A.
    Al Saikhan, L.
    Plymen, C.
    Chilcott, J.
    Matiti, L.
    Nihoyannopoulos, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 227 - 228
  • [37] Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
    Kondo, Toru
    Henderson, Alasdair D.
    Docherty, Kieran F.
    Jhund, Pardeep S.
    Vaduganathan, Muthiah
    Solomon, Scott D.
    McMurray, John J. V.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (22) : 2233 - 2240
  • [38] Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF A Prespecified Analysis of FINEARTS-HF
    Yang, Mingming
    Henderson, Alasdair D.
    Talebi, Atefeh
    Atherton, John J.
    Chiang, Chern-En
    Chopra, Vijay
    Comin-Colet, Josep
    Kosiborod, Mikhail N.
    Saraiva, Jose F. Kerr
    Claggett, Brian L.
    Desai, Akshay S.
    Tung, Chiao
    Kolkhof, Peter
    Viswanathan, Prabhakar
    Lage, Andrea
    Lam, Carolyn S. P.
    Senni, Michele
    Shah, Sanjiv J.
    Rohwedder, Katja
    Voors, Adriaan A.
    Zannad, Faiez
    Pitt, Bertram
    Vaduganathan, Muthiah
    Jhund, Pardeep S.
    Solomon, Scott D.
    Mcmurray, John J. V.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (02) : 120 - 136
  • [39] Effect of dapagliflozin on RV function in diabetic hypertensive women with HFpEF
    Mindadze, K.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 17 - 17
  • [40] Association among cardiopulmonary and metabolic rehabilitation, arrhythmias, and myocardial ischemia responses of patients with HFpEF or HFmrEF
    Hossri, C. A. C.
    Araujo, F. C.
    Baldi, B. G.
    Otterstetter, R.
    Uemoto, V. R.
    Carvalho, C. R. R.
    Mastrocola, L. E.
    Albuquerque, A. L. P.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2024, 57